Background: Marburg virus disease (MVD) is a highly virulent viral hemorrhagic fever with reported case fatality rates of up to 90%. It is part of the same family as the Ebola virus (Filoviridae). MVD, originally identified in 1967 in the context of outbreaks associated with African green monkeys, has been reported sporadically in Africa. Recent outbreaks, including those in Equatorial Guinea and Rwanda, underscore the need for robust preparedness systems and global response. Objectives: This narrative review focuses on the pathogenesis, clinical manifestations, diagnostic challenges and treatment strategies regarding MVD. It also stresses the need for better surveillance, diagnostic capabilities and vaccines to help prepare for future outbreaks. Methods: A comprehensive review of clinical data, epidemiological trends, and diagnostic developments was performed by searching relevant literature in PubMed, Medline and Scopus. The relevant data were extracted from studies on MVD and presented as a narrative review. Findings: MVD primarily affects immune and endothelial cells, resulting in a consequent cytokine storm, coagulopathy, and multi‑organ failure. Early symptoms such as fever, headache and myalgia are nonspecific and can delay diagnosis, as they mimic other infections. Monoclonal antibodies and newer antiviral agents are presently being evaluated for the management of MVD. Conclusions: MVD leads to significant morbidity and mortality, and the high fatality rate, along with the absence of targeted therapies, represents a serious global health threat. Collectively, the establishment of infrastructure for diagnostics, global collaboration, and advanced vaccine development will help bolster the response to MVD outbreaks and thus shorten periods of spiking mortality.
Objectives: The aim of this study was to evaluate the effectiveness of recombinant human bone morphogenetic protein‐2 (rhBMP‐2) coated biphasic calcium phosphate (BCP) in socket preservation in comparison to BCP.Material and Methods: Patients who underwent extraction of maxillary premolars were randomized to receive rhBMP‐2/BCP (n = 15) and BCP alone (n = 15). All sites were primarily closed using a pedicled connective tissue flap. Biopsy was carried out in patients at 3 (n = 10), 6 (n = 10), and 9 (n = 10) months.Results: At 3 months, BMP and non‐BMP groups had 3.17% and 3.12% new bone formation, respectively, and 3.8% and 37.85% of residual grafts, respectively, and 25.86% and 25.99% connective tissue component, respectively. At 6 months, both groups revealed 67.42% and 16.55% essential bone growth, 1.74% and 3.04% of residual graft, and 1.3% and 67% connective tissue component, respectively. At 9 months, the BMP group revealed 93.6% new bone formation, 0.68% residual graft, and 1.9% connective tissue component, while the non‐BMP groups had 23.35% new bone formation, 4.45% residual graft, and 44.06% connective tissue component.Conclusion: This study demonstrated that rhBMP‐2 coated BCP significantly enhanced early graft substitution in socket preservation sites compared to BCP alone. There was a significantly higher percentage of new bone formation in the rhBMP‐2/BCP group both at 6 and 9 months. Additionally, the rhBMP‐2/BCP group exhibited faster resorption of the graft material and earlier maturation of newly formed bone. These findings strongly suggest that rhBMP‐2/BCP can be an effective treatment modality for socket preservation, promoting predictable and accelerated bone regeneration.
This case report aimed to illustrate the management of single tooth replacement in the esthetic region using immediate implant placement, highlighting the importance of interdisciplinary treatment planning and adherence to esthetic principles. A 37‐year‐old female presented with a fractured upper front tooth, necessitating immediate attention to restore esthetic.